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Background. Treating hepatitis C with interferon/ribavirin results in a varied response in terms of decrease in viral titer and
ultimate outcome. Marked responders have a sharp decline in viral titer within a few days of treatment initiation, whereas in
other patients there is no effect on the virus (poor responders). Previous studies have shown that combination therapy
modifies expression of hundreds of genes in vitro and in vivo. However, identifying which, if any, of these genes have a role in
viral clearance remains challenging. Aims. The goal of this paper is to link viral levels with gene expression and thereby
identify genes that may be responsible for early decrease in viral titer. Methods. Microarrays were performed on RNA isolated
from PBMC of patients undergoing interferon/ribavirin therapy. Samples were collected at pre-treatment (day 0), and 1, 2, 7, 14
and 28 days after initiating treatment. A novel method was applied to identify genes that are linked to a decrease in viral titer
during interferon/ribavirin treatment. The method uses the relationship between inter-patient gene expression based
proximities and inter-patient viral titer based proximities to define the association between microarray gene expression
measurements of each gene and viral-titer measurements. Results. We detected 36 unique genes whose expressions provide
a clustering of patients that resembles viral titer based clustering of patients. These genes include IRF7, MX1, OASL and OAS2,
viperin and many ISG’s of unknown function. Conclusion. The genes identified by this method appear to play a major role in
the reduction of hepatitis C virus during the early phase of treatment. The method has broad utility and can be used to analyze
response to any group of factors influencing biological outcome such as antiviral drugs or anti-cancer agents where microarray
data are available.
Citation: Brodsky LI, Wahed AS, Li J, Tavis JE, Tsukahara T, et al (2006) A Novel Unsupervised Method to Identify Genes Important in the Anti-viral
Response: Application to Interferon/Ribavirin in Hepatitis C Patients. PLoS ONE 1(1): e584. doi:10.1371/journal.pone.0000584
INTRODUCTION
Treating with peginterferon/ribavirin combination therapy pa-
tients who have chronic hepatitis C virus (HCV) infection results in
a varied response in terms of outcome and decrease in viral titer
[1–4]. For patients who respond well there is a sharp decrease in
viral titer within 24–48 hours after treatment initiation whereas in
other patients there is little or no effect on the viral titer and only
temporary, or no, clearance of the virus over a long period [5,6].
Previous in vitro studies have shown that combination interferon
treatment induces or decreases expression of hundreds of genes
[7–10]. One of the major problems, however, is to identify which
of these genes are linked to viral clearance in vivo.
In this paper we report a novel mathematical method to explore
the association between decrease in viral titer and changes in gene
expression in hepatitis C patients following combination treatment
with pegylated interferon and ribavirin. The viral clearance time
course profile will not necessarily directly correlate with the gene
expression time course profile even if the gene is an active
participant of the interferon treatment response because the
decrease of the viral levels depends on the interplay of many genes
and gene products. Therefore, an indirect approach was used in
which the relationship between gene expression across days and
viral decrease was examined using inter-patient distances (prox-
imity) according to both characteristics.
Using this approach we selected thirty seven gene probes that
were linked with the anti-HCV response during the first 28 days of
treatment. A visual demonstration of the association of detected
genes with the viral decrease is demonstrated by a comparison of
patient clusterings. Indeed, the inter-patient proximities according
to the pattern of decrease in virus titer provide an unsupervised
clustering of patients based on changes in viral levels. Similarly,
the inter-patient proximities according to expressions of the
specified genes across time provide another unsupervised cluster-
ing of patients. A visual inspection of viral-titer based and selected
genes expression based clusterings of patients indicates their close
relationship. Since the unsupervised clustering of patients accord-
ing to the pattern of viral clearance is in good correspondence with
an a priori biological categorization of patients into marked, slow
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be considered as genes that are involved specifically in treatment
response. Such genes products may have anti-viral activity or be
related to the immune response against virus-infected cells.
MATERIALS AND METHODS
Patient population
The Virahep-C study included a cohort of 401 participants who
provided written consent at 8 U.S. clinical centers between
September 9, 2002 and January 7, 2004. Per protocol, all
participants were treated for up to 48 weeks with pegylated
interferon alfa-2a (PEGASYS, Roche Inc. Nutley, NJ) at 180 mcg
weekly by self-administered subcutaneous injection and ribavirin
(COPEGUS, Roche, Inc. Nutley N.J.) by mouth at 1000 mg/day
for those who weighed less than 75 kg or 1200 mg/day for those
who weighed at least 75 kg. Treatment was discontinued at week
24 in participants who had a detectable serum HCV RNA virus in
duplicate qualitative assays using the Roche Cobas Amplicor
HCV Test, v2.0 (sensitivity 50 IU/ml). The primary endpoint of
the study was the sustained virologic response, defined as an
undetectable serum HCV RNA at week 72 (at least 24 weeks after
completion of treatment). The clinical trial was #-NCT00038974.
Fifty two patients for whom gene expression and viral level data
were available at all time points were selected for this analysis.
Based on the log-decline in serum HCV RNA on day 28 of
treatment relative to day 0, as measured by the quantitative Roche
Cobas Monitor HCV Test, v2.0 (sensitivity 600 IU/ml) these
patients were divided into three groups [11] Patients were
identified as poor responders if they had less than a 1.4 log10
IU/ml decrease in serum HCV RNA between day 0 and day 28,
as marked responders if they experienced more than a 3.5 log10
IU/ml decrease or if their viral titers dropped to undetectable by
day 28, and as intermediate responders if the log10 drop in HCV
RNA was between 1.4 and 3.5 IU/ml. For the purpose of
unsupervised clustering of viral titers, patients with undetected
viral levels by the quantitative assay were assigned a viral level of
599 IU/ml and those whose viral levels were undetected by the
qualitative assay were assigned a viral level of 49 IU/ml
This study met all necessary approvals of Institutional Review
Boards of each institution participating inthe Virahep-C consortium
(Beth Isreal Deaconess Medical Center, New York Presbyterian
Medical Center, Rush University, University of California at San
Francisco, University of Maryland, University of Miami, University
of Michigan, and University of North Carolina).
Cell preparation and RNA extraction
Peripheral Blood Mononuclear Cells (PBMC) were collected in
sodium heparin-CPT tubes at day 0, 1, 2, 7, 14 and 28. Samples
were shipped overnight from each clinical center to a central
repository by express courier at 4uC. Whole blood was diluted with
an equal volume (8 ml) of phosphate buffered saline, carefully
layered over a 10 ml Ficoll-Hypaque gradient (Amersham/
Pharmacia) and centrifuged at 800 rpm for 20 minutes at room
temperature. The buffy coat layer was transferred to a 15 ml
RNAse-free tube and further diluted with PBS. Tubes were
centrifuged at 100-6g for 15 minutes at room temperature. The
supernatants were discarded and the PBMC were retained.
The isolation of RNA, quality control, the labeling and hybridiz-
ation on to the micro-arrays have been previously described [7,10].
Array Analysis and Data Processing:
The microarrays were scanned using a dedicated Model 3000
scanner controlled by Affymetrix Microarray Suite 5 software
(MAS5). The average intensity on each array was normalized by
global scaling to a target intensity of 1000. Data were exported
from MAS5 into a custom-designed database (MicroArray Data
Portal) in the Center for Medical Genomics (IUPUI, Indianapolis).
The data from the microarrays has been deposited with NCBI,
GEODATA# GSF7123
Visualization of patient grouping
Visualizing the patient data was simplified through Principal
Component Analysis (PCA) [12] which reduces the dimensionality
of the data into a small number of independent components. An
alternative method to present data grouping is hierarchical
clustering. We used the hierarchical clustering (UPGMA) [13]
algorithm for the clustering.
Both PCA and the clustering of patient’s groupings according to
either viral titer or gene expression data were performed to
visualize the correspondence between predefined grouping of
patients (marked, intermediate, and poor, highlighted by color)
and either gene expression or viral titer based grouping of patients.
Viral titer based proximity of patients and
‘‘candidate’’ genes
Detection of genesthatprovided clusteringsimilar to viral titer based
clustering of patients was performed by a mathematical method
similar to the mirror tree method for inferring protein interactions
from phylogenetic distance matrices [14,15]. This method was
applied to gene expression and linked the gene-specific variability of
patients with their viral titer variability. The link is a correlation
between the matrix of inter-patient distances that is based on viral
titer and the individual gene expression based matrix. If a gene
expression based matrix correlates with a viral titer matrix, then it
can be concluded that there is a link between expression of that
specific gene and the viral levels in patients. Such a link considers
both the direct correlation between the expression profile of a gene
across patients and the viral titer pattern of patients, and the indirect
involvement of the gene in the viral level change process. A detailed
description of the method follows.
The distance between patients’ viral titer changes from day 0 was
used to estimate the inter-patient proximity with respect to viral
change. Similarly, the gene expression based inter-patient proximity
was measured for each gene. The correlations between each gene
based matrix proximity and viral titer based matrix-proximity were
estimated and genes with the highest correlations were selected.
As metrics of inter-patient proximity two measures were used:
Euclidean distance and the coefficient of covariation. The larger the
coefficient of covariation, the closer the patients are whereas the
smaller the Euclidean distance the closer the patients are. Thus, the
inter-patient distances based on viral titer time-coursemeasurements
created a grouping of patients that reflected the response of patients
to antiviral treatment. On the other hand, the inter-patient
proximities based on gene expression measurements across days
(gene expression profile) for a specific gene reflected the variability of
patients either according to response of this gene to treatment, or
according to genetic heterogeneity of patients, or both.
The Euclidean distance between the natural logarithms (ln) of
changes in viral levels from baseline (day 0) for patient i and
patient j was defined as:
Vij~
X
d~1,2,7,14,28
((ln(vid){ln(vi0)){(ln(vjd){ln(vj0)))
2
where vid is the viral titer value for i
th patient on day d. Denote
V~fVij,1ƒivjƒkg as the vector of Euclidean distances
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the number of patients.
Similarly, the inter-patient Euclidean proximities with respect to
the natural logarithm (ln) of the gene expression for the r
th gene on
day d were estimated by
Grd
ij ~((ln(gr
id){ln(gr
i0)){(ln(gr
jd){ln(gr
j0)))
2,
where g
r
id is the expression of r
th gene for i
th patient on day d. Let
G
rd
~fGrd
ij ,1ƒivjƒkg denote the vector of inter-patient prox-
imity according to expression of r
th gene at day d. Corresponding
to Vij, define Gr
ij~
X
d~1,2,7,14,28
Grd
ij to be the inter-patient Euclidean
proximities with respect to the gene expression for the r
th gene.
Denote vectors G
r
~fGr
ij,1ƒivjƒkg with dimension k(k21)/2.
The inter-patient proximities according to expression of
all genes was then estimated by the vector of the same k(k21)/2
dimension G~fGij,1ƒivjƒkg, where Gij~
X N
r~1
Gr
ij, where
N is the number of genes on the array. Note that
G~
X N
r~1
G
r
~
X N
r~1
X
d~1,2,7,14,28
G
rd
We will refer to the vectors G ¯ rd and G ¯ r as GDeu and Geu
vectors respectively. Vector G ¯ will be referred to as the main
vector (MVeu) of the method and has equal biological importance
to the virus titer related vector V ¯ (VTeu) . Indeed, MVeu is the
vector of distances between each pair of patients across all genes
and all days. These distances reflect differences between patients
both due to individual variability and due to the response of
patients to the combination treatment. Thus, inter-patient
distances across all genes and all days are the superimposition of
patient’s individual and response differences. The norm of MV is
a cumulative measure of how patients are divergent according to
their gene expression. Genes that are not co-regulated (the
majority of them) have random distances with other genes thus
making a minimal impact in the length of the MV. Indeed, gene
vectors G with random signals are distributed symmetrically in
k(k21)/2 space. Under summation they will compensate each
other, reducing the norm of the MV vector. Therefore, a large
norm for MV is defined by a relatively small number of co-
regulated groups of genes, and these groups are related to the
biological divergence of patients (including the divergence of their
response). From a biological point of view it is important to
understand whether the input of genes in MV is correlated with
the virus titer vector VT in k(k21)/2 space. If they are, then the
variability of patients according to gene expression is closely
related to their treatment response; if not, then gene expression
variability of patients is defined by their other characteristics.
Similarly to Euclidean distance based vectors G ¯ rd, G ¯ r, G ¯ and V ¯
of the k(k21)/2 space, the covariance based vectors G ¯ rd,cov,
G ¯ r,cov, MVcov (G ¯ cov) and VTcov (V ¯ cov) of the same space k(k21)/2
were defined as follows. The element of VTcov vector is thus
Vcov
ij ~
X
d~1,2,7,14,28
(jid{ji):(jjd{jj), where
jid~ln(vid){ln(vi0), and ji is the average of jid across
Figure 1. The clustering of 52 patients according to viral titer measurements across days. All viral titer values of each patient are normalized by the
same patient day 0 viral titer measurement. The Euclidean measure based hierarchical (UPGM) clustering indicates a good separation of the early
response Marked (pink) and Poor response (green) patients. The Slow (yellow) patients are mostly concentrated at the intermediate branch of the
clustering tree.
doi:10.1371/journal.pone.0000584.g001
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th
gene, G
r,cov
ij ~
X
d~1,2,7,14,28
(b
r
id{bi):(b
r
jd{bj), where
b
r
id~ln(gr
id){ln(gr
i0) and b ¯ i is the average of b
r
id across all
genes and all days.
The associations between vectors G, GD and vectors MV and
VT both for Euclidian and Covariance metrics were estimated by
the Pearson correlation coefficients. We assume that (i) the expres-
sion of the gene log-signal in a patient is normally distributed, (ii)
expression values of a gene across patients are independent, and
(iii) for all genes there are no dependences of between-patient
distances according to gene expression and between-patient
distances according to viral titer values. The method detects
linkage of genes with viral titer as statistically significant deviations
against the point (iii), i.e., differences in correlation coefficients
from 0. The statistical significance of correlation coefficients may
be calculated using Fisher’s Z transformation[16] for correlation
coefficients which is distributed normally with mean zero and
variance 1/[{k(k21)/2}23]. We can alternatively estimate the
significance of R
2 (the square of the correlation coefficient) assuming
a beta distribution with 0.5 and k(k21)/2 degrees of freedom. If we
take into consideration that there is a weak mutual depend-
ence between each pair of patient distances with the same patient is
in both pairs, the significance estimation according to beta distribu-
tion with 0.5 and k(k21)/4 degrees of freedom will compensate this
weak mutual dependence of inter-patient distances.
MV and VT relationship and selection of VT-linked
genes
In order to take into account both Euclidean and Covariance
measures of proximity in the selection of VT-linked genes, the
analysis was done as follows. A multidimensional scaling[17] was
applied to reduce the dimensionality of the k(k21)/2 space.
Namely, the mutual proximities of gene (G) and gene-day (GD)
vectors estimated through their correlations with MV and VT
vectors (vectors are prepared according to Euclidean and covari-
ance measures) were represented by two-dimensional Euclidean
distances in the principal component analysis (PCA) [12] space.
Two principal components (PC1 and PC2) were detected accord-
ing to 8 initial variables, these variables being correlation coeffi-
cients for vector pairs (Gcov-MVcov), (GDcov-MVcov), (Gcov-
VTcov), (GDcov-VTcov), (Geu-MVeu), (GDeu-MVeu), (Geu-
VTeu), (GDeu-VTeu) across all gene-days. The first principal
component appears to be defined by correlations of G and GD
vectors with MVcov and MVeu vectors, and the second one by
Figure 2. The PCA visualization of inter-patient proximities according to day 0 normalized per day viral titer values. First two Principal
Components cover 93% of data variability and thus gives the good presentation of the patient distribution in the 5 dimensional space. There is the
clear divergence of Marked (dark blue points) and Poor (green points) response patients. The separation line (dotted blue line) indicates the virtual
border between these two populations. Slow patients (pink points) are mostly concentrated along the borderline.
doi:10.1371/journal.pone.0000584.g002
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This implies that gene (G and GD) correlations with two MV
vectors are independent from gene correlations with two VT
vectors, and therefore the general variability of patients according
to gene expression is not related to the response to the
combination therapy of patients.
The deviation of some GD-vectors from the core of their
distribution in the multi-scaling space in the direction of VT vectors
(i.e. at PC2 direction) indicates a link of these gene-days (and genes)
with viral titers. As the initial criterion for gene-day detection the
PC2.threshold was used. The statistical significance of such gene
detection was checked by Fisher’s Z-test and via beta distribution for
correlation coefficients of G(GD) vectors regarding VTcov vector.
Both tests used an adjusted number of degrees of freedom to
compensate for a weak inter-dependence of vector coordinates.
The more accurate check of the gene detection significance and
the estimation of False Discovery Rate (FDR) were performed
through permutations. In the first step the distribution of
‘‘random’’ gene-days in the multiscaling space was prepared
through permutation of gene-days log-signals over 52 patients of
the study. After that correlations of permutated gene-day based
inter-patient matrices with VT and MV vectors in k(k21)/2 space
were calculated, and the previously found transformation of the
initial 8-dimension space into the multiscaling space was applied to
these correlations.
The FDR estimation for the detected set of real genes was done
as follows. The sub-space that the gene set is occupied in the
multiscaling space was defined as the sphere around the central
position of this set. The ratio of the number of permutated gene-
days inside the sphere (normalized to the size of real gene set) to
the number of the real gene-days inside the sphere is the False
Discovery Rate estimation for a sphere of the given radius.
RESULTS
As a first step, the correlation between patient classification based
on decrease in virus titer by day 28 and the unsupervised viral titer
based clustering of patients was tested. Namely, natural log-
transformed viral titers of the 52 patients were normalized using
the baseline viral level (i.e. day 0) [i.e. ln(vi )2ln(v0) ], where vi is
the viral titer value at day i. The clustering of patients was done by
the hierarchical UPGMA method [13] using a Euclidean measure
of similarity. The branches of the clustering tree (patients) were
labeled by type of response according to the initial categorization
of the early response (marked, intermediate, and poor) [11] (Fig 1).
This hypothesis-free clustering based on inter-patient Euclidean
distances according to viral titer demonstrated that patients could
be placed into three groups corresponding to the response
classification of patients. Indeed, the biggest and most compact
cluster consists of poor response patients (the left branch of the
tree). The right branch of the cluster contains just marked response
patients. The middle branch of the cluster contains a mix of all
three classes of patients. If only poor and marked response patients
are considered, then there is no misclassification for extreme right
and left clusters of the hierarchical classification.
Another compact visualization of patient grouping according to
the same baseline-normalized viral titer data was performed using
PCA. The first two principal components covered 93% of total
data variability. The distribution of patients using the classification
given above demonstrated clear separation of poor response
patients from marked response patients (Fig 2, see separation line).
In the second step, the viral titer linked genes were determined.
We defined VT-linked genes as the ones that produced a clustering
of patients similar to viral titer based clustering of patients. The
procedure for their detection was as follows: Gene expression for
each day was normalized with regard to day 0 expression, as was
Figure 3. The schematic representation of the algorithm’s main idea. Any matrix of inter-patient distances for k patients could be presented as
a point (vector) in k (k21)/2 dimensions space. There are two main vectors in this space; the inter-patient matrix according to viral titer (blue dotted
vector) and inter-patient matrix according to expression of all genes (black vector). The expression of every gene is presented as a point (vector) in
the same space: the inter-patient matrix according to the expression values of this gene. Some genes could be close to viral-titer vector VT or/and to
all gene expression vector MV. Inter-patient matrices according to expression of individual genes (G) at specific days (GD) are dots of the figure.
Points of high correlation with VT vector (pink dots) are VT-linked genes. MV linked genes (green dots) define individual variability of patients
according to their gene expression. The genes not linked with the two main vectors genes are in red.
doi:10.1371/journal.pone.0000584.g003
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hypothesis that the between-patient proximities according to gene
and gene-day expression pattern of specific genes are correlated
with the viral titer based inter-patient proximities. Thus we looked
for genes (gene-days) that ‘‘associated’’ with the viral titer. The
selection was done through multidimensional scaling PCA
representation for the space of correlations between inter-patient
distance matrices (Fig 3). The deviations of some GD-vectors from
their uniform distribution in the PCA space in the direction of VT
vectors (Fig.4, pink dots) indicated a link of these gene-days (and
genes) with viral titer behavior of patients. Thus, gene-days with
the second principal component (PC2) value more than 5 were
selected. Genes having less than 3 gene-days with PC2 greater
than 5 were filtered out.
The correlation coefficients of all detected genes with VTcov (as
representing VT group of inter-patient matrices) are more that
0.24 (Table S1) which corresponds to a p-value of less than 1.0E-
08 for 1326 (52*51/2) degrees of freedom.
The permutation analysis (see M&M) was based on 1000
permutations of gene-day signals across all 22000 genes at 5 days.
The minimal radius of the sphere that covers 80% of gene-days of
the selected 37 genes in the 4-mer multi-scaling space is 2.6. This
radius corresponds to FDR 1% of the detection. The four
dimensional multi-scaling space was taken because such a number
of PCA components cover more than 80% of gene expression data
variability.
Most of detected genes (Table 1) have been identified previously
as interferon induced in PBMC or A549 cells in vitro [7,18]
supporting the conclusion that these are meaningful genes
although they were identified in an unsupervised manner. Table
S1 lists the top 37 probe sets with details of each probe set and
with the day-by-day correlations between gene expression and
viral titer.
Visualization of the sources of variation of patients according to
gene expressions of genes- classifiers was simplified through PCA,
which reduced the dimensionality of the data into a relatively small
number of components. PCA presentation is illustrated in Figure 5.
The baseline-normalized expression of these 37 genes (probe sets)
appears to be a good discriminator of Marked vs. Poor. Indeed,
the PCA presentation of the distribution for 52 patients according
to expression profiles across all days of these 37 probe sets
demonstrates the obvious shift of poor response patients to
negative values of the component 1 (Fig 5). The PCA presentation
of the data distribution is relevant because the first two
Figure 4. The two-dimensional PCA representation (cover 63% of data variability) of inter-vector correlations in k (k21)/2 space – the space of
distances between inter-patient matrices. One may interpret this figure as the view from above on Fig. 3 schema. Follow to multidimensional-
scaling method the proximities between gene based inter-patient matrices as estimated through their correlations with MV and VT matrices were
represented by inter-gene (gene-days) Euclidian distances in the PCA two-dimensional space. Positions of VTeu, MVeu (Euclidean metrics) and VTcov,
MVcov (covariance metrics) matrices in the PCA space are seen on the insert. VT linked genes are denoted by pink dots. MV-linked genes are in the
frame on the figure right.
doi:10.1371/journal.pone.0000584.g004
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data variability. One can see the same basic separation of marked
vs. poor response patients in clustering in Fig. 6.
DISCUSSION
The goal of this paper is to link heterogeneous sets of observations
(gene expressions and viral levels) without an a priori hypothesis.
We developed a mathematical model that can be applied to any
situation using gene expression and viral titer or any other
attributes. Application of this approach to patients treated with
interferon/ribavirin is based on the assumption that distances
between sets of patient’s attributes reflects a biological demarca-
tion of patients. As patient attributes we applied the following
measurements: (i) viral titer profile during the first four weeks of
treatment (viral levels on days 0, 1, 2, 7, 14, and 28), and (ii) the
expression of all 22,000 genes of the Affymetrix array across the
time course of the treatment.
The difference among patients according to all 22,000 genes on
the array reflects the overall gene expression heterogeneity of
hepatitis C patients undergoing interferon/ribavirin treatment.
This could be due to differences in response, to genetic
heterogeneity, or to difference in arrays and handling of RNA.
The differences between patients according to any single gene
reflect the gene-specific variability of the hepatitis C patients. The
gene-specific variability that correlates with the viral titer
variability is what is analyzed in this paper and which may be
independent of the above. No differences were found in gene
expression in an analysis of RNA isolated from PBMC before
treatment, when patients were divided into responders and non-
Table 1. Genes hypothesized to be important in the anti-hepatitis C response.
..................................................................................................................................................
Gene name Unigene ID Genbank ID Gene description
BLZF1 Hs.494326 U79751 Basic leucine zipper nuclear factor.
DDX58 Hs.438386 NM_014314.1 RIG 1 ( helicase)
DNAPTP6 Hs.230767 AK002064.1 DNA polymerase activated protein
EIF3S6IP Hs.446852 AA862804 Eukaryotic initiation factor 2.
EPHB2 Hs.523329 AI038197 Ephrin B/tyrosine kinase receptor family.
FLJ20035 Hs.481141 AI093428 Helicase
FLJ38348 Hs.546523 AV755522 coiled-coil domain 75 ( CCDC75):RNA binding proteins
G1P2 Hs.458485 NM_005101.1 ISG15 ubiquitin—like modifier.
G1P3 Hs.287721 NM_022873.1 IFI6: inhibitor of apoptosis
HERC5 Hs.26663 AA905126 Ubiquitin ligase 5
HERC6 Hs.435365 NM_017912.1 Ubiquitin ligase
IFI27 Hs.532634 AA991433 Unknown function
IFI44 Hs.82316 BE049439 hepatitis C associated microtubule protein.
IFI44L Hs.389724 NM_006820.1 histocompatibility 28
IFIH1 Hs.389539 NM_022168.1 Helicase domain 1.
IFIT1 Hs.20315 AA975472 IFI56, Induced protein with tetratricopeptide repeats-1.
IFIT3 Hs.47338 AA991285 Interferon-induced protein with tetratricopeptide repeats 3, ISG60
IFIT5 Hs.252839 N47725 IFI58, induced proteins with tetratricopeptide repeats. 5
IFRG28 Hs.43388 AA970212 Receptor transporter 4
IRF7 Hs.166120 AA991566 Interferon regulatory factor 7
LAMP3 Hs.518448 BX116004 lysosomal associated membrane 3.
MX1 Hs.436836 NM_002462.1 GTP-binding protein
MX2 Hs.926 AI015252 Dynamin and GTPase family
OAS2 Hs.414332 NM_016817.1 2959Oligo A synthetase 2, 69/71kD.
OASL Hs.118633 CB125965 2–5 oligo A synthetase like.
PABPC4 Hs.169900 T05603 Inducible Poly A binding protein
PCTK3 Hs.445402 BC000281.1 PCTAIRE protein kinase 3
PLSCR1 Hs.130759 AI825926 Phopholipid scramblase: enhances anti-viral gene response.
RPL22 Hs.515329 BE250348 60 S ribosomal protein: EB virus binding protein
RSAD2 Hs.17518 AI337069 viperin, cig 2.
SAMD4 Hs.98259 AB028976.1 translation regulator.
SN Hs.31869 N53555 Sialoadhesion
SNF7DC2 Hs.415534 NM_015961.1 chromatin modifying protein 5 (CHMP5)
TBX3 Hs.129895 NM_006187.1 T-box transcription factor 3.
TRIM5 Hs.350517 AF220028.1 tripartite motif-containing 5
USP18 Hs.38260 AA976038 Ubiquitin specific peptidase
doi:10.1371/journal.pone.0000584.t001
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PLoS ONE | www.plosone.org 7 July 2006 | Issue 1 | e584responders. Thus the differences are reflection of treatment rather
than a reflection of the course of hepatitis C infection.
The gene-specific divergence of patients is checked against the
overall patient divergence according to all genes. It appears that the
process of virus clearance by interferon/ribavirin is not the major
part of the overall gene expression pattern. Indeed, VT-linked genes
(genes identified as viral clearance related) make a rather small input
into the MV vector, which represents the pattern of overall gene
expression variability of patients (Fig.3 and 4).
We examined the variability of patients according to changes in
viral titer with time. This analysis demonstrates that the clustering
of patients [Fig. 1] according to viral titer largely matches the
a priori definition for classification of patients (marked, in-
termediate, poor) used in this and earlier papers [11]. Although
there are a few outliers, in general our initial division using day 28
viral titer appears to have biological as well as mathematical
relevance. Even though the a priori classification of patients was
based solely on the viral decline at day 28 relative to day 0, the
unsupervised clustering of patients based on viral titers at all
6 days resulted in similar clusters, indicating that patterns of viral
declines for marked, intermediate and poor response patients are
different in-between day 0 and day 28. Since the clustering of
patients according to the viral titer profiles is in good correspon-
dence with patient classification (Fig. 1,) the selected 37 probe sets
(table 1 and table S1) could be considered as genes that are
important in the anti-viral and immune response to interferon/
ribavirin therapy.
A very large number of genes are modified by the treatment in
vitro of PBMC with interferon and ribavirin [7,19]. Similar results
have been found recently following the treatment of A549 cells
and Huh 7 cells with IFN-acon1 [10]. Many of the genes listed in
table 1 are known to be involved in the interferon response from in
vitro studies [7,10,18]. In most cases the level of induction for these
genes was much lower in poor response patients than in marked
patients, as would be expected from the relationship to viral titer.
Among the genes we identified as important is IRF-7. This gene
is required for the induction of type I interferons [20–23] and is an
important component of the Toll signaling pathway [24]. Studies
using LPS have indicated that IRF-7 plays an important role in
LPS induced B7.1 activation through the JNK system [25]. B7-1 is
an important co-stimulatory factor required for T-cell activation.
Binding of TLR7 and activation of the NFkB pathway via IRF-7
[26] is required for the endogenous production of interferon-alpha
and beta. Thus the levels of IRF-7 may be important in the overall
Figure 5. The PCA presentation of the divergence between Rapid and poor response patients according to day 0 normalized expression of 35
VT-linked genes across other days. Two first principal components cover 63% of the data variability. The virtual border line between distributions of
Marked and Poor response patients gives three misclassified Marked patients and four misclassified Poor response patients.
doi:10.1371/journal.pone.0000584.g005
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PLoS ONE | www.plosone.org 8 July 2006 | Issue 1 | e584patient response [23], and the endogenous production of IFN-a or
IFN-b would certainly lead to further anti-viral effects. Another
gene recently reported to be involved in the signaling of the
interferon response, is RIG-I, a key ds-RNA sensor protein.
Activation of RIG-I (DDX58) leads to the induction of IRF-3,
IRF-7, and NFkB [27–29]. This pathway is blocked in vitro in
hepatitis C infection by the NS3/4A protein of the virus [29].
However it is unlikely that this occurs in PBMC, since there is no
evidence that PBMC are widely infected with the virus. IFIH1 is
also a DEAD protein with a helicase domain. Its relationship to
RIG-I is unknown. Among the other genes listed in Table 1, many
have been describes as part of the initial response in vivo (in
Chimpanzees) to hepatitis C infection, and are the results of
endogenous interferon production. These include cig 5, (RSAD2),
IFI44, MX1, and the OAS genes [30]. Viperin (cig5) has also been
reported as being induced in the liver in human patients during
hepatitis C infection, presumably by endogenous interferon or
double-stranded RNA [31]. It has been proposed that this gene
product has anti –hepatitis C activity [31]. PLSCR1 has also been
shown to potentiate the anti-viral activity of interferon . When
PLSCR1 expression was decreased by siRNA, higher titers of VSV
and EMC were obtained [32]. G1P3 (IFI-16-6) may function as
a cell survival protein by inhibiting mitochondrial-mediated
apoptosis through the inhibition of caspase 3 activity [33]. Its
role in the anti-viral response or anti-hepatitis response is
unknown. .. Many of the genes on this list have unknown
functions (IFI27, IFIT1, IFIT5, , IFI44, IFI44L, LAMP 3, ,
FLJ20035, IFRG28, DNAPTP6). Other genes are involved in
transcription regulation including RGL1, and TBX3 or translation
repression (SAMD4).). PABPC4 is also known as inducible poly(A)
binding protein and is upregulated in activated T-cells, but not in
resting T-cells [34]. However in this study it was slightly down
regulated. It also appears to be involved in the regulation of IL-2
[35]. G1P2 is identical to ISG15. This protein is a ubiquitin-like
protein which is conjugated to many cellular proteins [36]. It
appears to interfere with protein poly-ubiquitination and protein
degradation. Its role in the interferon response is unknown,
although it is highly induced. USP18, a member of the de-
ubiquitinating protease family of enzymes, removes ubiquitin
adducts from a broad range of protein substrates. Herc 5 and Herc
6 belong to a family of ubiquitin ligases. Thus many genes involved
in protein modification are essential to the anti-viral response. SN
(Sialoadhesion) very highly induced both in vitro and in vivo is
a member of the sialic acid binding immunoglobulin ( Ig)-like
lectins. And is primarily expressed in resident and inflammatory
macrophage populations [37], [38]. SN deficient mice exhibit
changes in B and T-cell populations and it is proposed that this
molecule regulates the immune system [39].
Two genes that are down regulated correlate with the viral
response: RPL22 (ribosomal protein L22), a component of the 60S
ribosome, and eukaryotic translation initiation factor 3, subunit 6
interacting protein. Whether this decrease is involved in virus
inhibition through modifying IRES-dependent translation of the
HCV genome is speculative.
It is of interest that not only inducible genes appear to be a major
component of the interferon response, but also down regulation
(repression) of a translation factor and ribosomal protein.
Since this was an unsupervised analysis and did not take into
account A/P ( absence/present) filtering, some of the genes are
possibly not involved in the anti-viral response, since they were not
present in specific classes of patients as analysed with MAS5 soft
ware. These include BLZF1, EPHB2, PCTK3 and SNF7DC2
Figure 6. The Euclidean measure based hierarchical (UPGM) clustering of patients according to day 0 normalized expression of 35 VT-linked
genes across other days. Marked (pink) and Poor response (green) patients are mostly separated in two branches of the tree. There are three Marked
and six Poor response patients misclassified.
doi:10.1371/journal.pone.0000584.g006
Identifying Linked Genes
PLoS ONE | www.plosone.org 9 July 2006 | Issue 1 | e584In summary we have identified key genes in the response to
interferon/ribavirin in hepatitis C patients using a novel method of
analysis. This is based on correlation with decrease in virus titer.
This method has broad utility and can be used to analyze response
to any group of factors influencing biological outcome.
SUPPORTING INFORMATION
Table S1 Contains 166 gene-days of 37 viral titer linked genes
(probe sets). Not less than 3 gene-days of the gene have component
PC2 values more than 5 (these gene-days are pink dots of the
Fig. 4). The component PC2 is PCA second component after
multidimensional scaling of 8 variables: correlation coefficients in
the space of (52*51)/2 dimensions between Gcov_MVcov,
GDcov_MVcov, Gcov_VTcov, GDcov_VTcov, Geu_MVeu,
GDeu_MVeu, Geu_VTeu, GDeu_VTeu for all gene-days.
Columns of the Table S1 are as follows: SID - Affymetrix probe
set ID; DAY - day of the treatment; Static_CA_1013 - log-
transformed and day0 normalized gene expression values [(Ln(di)-
Ln(d0))] for a patient 1013. The response based classification of the
patient and her/his race are identified in the patient’s name;
Slow_CA_1016; Rapid_AA_1018; .................. - 52 patients of the
study; VTeu_Geu - the following 8 columns are correlations
between corresponding vectors in the space of (52*51)/2
dimensions. These correlations are 8 initial variables for the
multidimensional scaling procedure; VTeu_GDeu; MVeu_Geu;
MVeu_GDeu; VTcov_Gcov; VTcov_GDcov; MVcov_Gcov;
MVcov_GDcov; GENE_SYMBOL - the following are gene
names and descriptions; LOCUSLINK; UNIGENE; GENBANK;
GENE; SOURCE_ID; DESCRIPTION; PC1 - the multidimen-
sional scaling first component; PC2 - the multidimensional scaling
second component.
Found at: doi:10.1371/journal.pone.0000584.s001 (0.23 MB
XLS)
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